May 19, 2023 05:03 PM EDTUpdated May 22, 07:21 AM

Updated: In another blow for NASH, FDA adcomm opposes accelerated approval of Intercept drug

Nicole DeFeudis

Editor

An FDA advisory committee on Friday voted against recommending accelerated approval of Intercept’s once-rejected NASH hopeful obeticholic acid, saying the risk-benefit profile didn’t stack up …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Updated: In another blow for NASH, FDA adcomm opposes accelerated approval of Intercept drug

Nicole DeFeudis

Editor

Sign up to read this article for free.

‭ Regulatory Lead / Head of Regulatory‬

Autonomy Bio Inc.

San Francisco, CA 94107, USA

China’s biotech market is staging a comeback that US biotech can only wish for

With aims to become a 'generational biotech,' Zealand Pharma hires Lilly veteran as science chief

Large vaccine makers stand by their investments despite US headwinds

Genentech vet launches ADC startup with $20M

Makary, in one of first comments on FDA policy, floats new pathway for rare disease drugs

ADSTILADRIN® (nadofaragene firadenovec-vncg) – A Growing Body of Clinical Data and Real-World Evidence

Up­dat­ed: In an­oth­er blow for NASH, FDA ad­comm op­pos­es ac­cel­er­at­ed ap­proval of In­ter­cept drug

Editor

Sign up to read this article for free.

Autonomy Bio Inc.

San Francisco, CA 94107, USA

Updated: In another blow for NASH, FDA adcomm opposes accelerated approval of Intercept drug